Abstract
After renal transplantation, hemolytic uremic syndrome (HUS) may occur either as a recurrent or de novo form. Over the past decade, much effort has been devoted to elucidating the pathogenesis of atypical HUS (aHUS). Approximately 60–70% patients with aHUS have mutations in regulatory factors of the complement system or antibodies against complement factor H. The risk of post-transplant recurrence of aHUS depends on the genetic abnormality involved, and ranges from 15% to 20% in patients with mutations in the gene that encodes membrane cofactor protein and from 50% to 100% in patients with mutations in the genes that encode circulating regulators of complement. Given the poor outcomes associated with recurrence, isolated renal transplantation had been contraindicated in patients at high risk of aHUS recurrence. However, emerging therapies, including pre-emptive plasma therapy and anti-C5 component monoclonal antibody (eculizumab) treatment have provided promising results and should further limit indications for the risky procedure of combined liver–kidney transplantation. Studies from the past 2 years have demonstrated genetic abnormalities in complement regulators in 30% of renal transplant recipients who experienced de novo HUS after renal transplantation. This finding suggests that the burden of endothelial injury in a post-transplantation setting may trigger de novo HUS in the presence of mild genetic susceptibility to HUS.
Key Points
-
Mutations in genes that encode components of the alternative complement pathway (for example, CFH, CFI, MCP, C3 and CFB) and anti-complement factor H antibodies have been identified in 60–70% of patients with atypical hemolytic uremic syndrome (aHUS)
-
Mutations in genes that encode regulatory factors of the complement system (for example, CFH, CFI and MCP) have been identified in 30% of cases of de novo post-transplant hemolytic uremic syndrome (HUS)
-
The risk of aHUS recurrence after renal transplantation varies according to which factor is mutated: the risk is low (∼15%) for mutations in membrane cofactor protein and high (∼80%) for mutations in circulating proteins
-
Post-transplant recurrence of aHUS is associated with a poor outcome; therefore living-donor renal transplantation is currently not recommended in the setting of aHUS
-
The multitude of endothelial aggressors in the post-transplant setting may trigger de novo HUS in patients with mild genetic susceptibility to HUS
-
Innovative therapeutic avenues, including pre-emptive plasma therapy and anti-C5 antibody therapy are extremely promising for the prevention or cure of recurrent aHUS, and should limit the indications for combined liver–kidney transplantation
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferraris, J. R. et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr. Nephrol. 17, 809–814 (2002).
Loirat, C. & Niaudet, P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr. Nephrol. 18, 1095–1101 (2003).
Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676–1687 (2009).
Bresin, E. et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin. J. Am. Soc. Nephrol. 1, 88–99 (2006).
Caprioli, J. et al. Genetics of HUS: the impact of, MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267–1279 (2006).
Kavanagh, D. & Goodship, T. H. Membrane cofactor protein and factor I: mutations and transplantation. Semin. Thromb. Hemost. 32, 155–159 (2006).
Pickering, M. C. et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 31, 424–428 (2002).
Pickering, M. C. et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 204, 1249–1256 (2007).
Dragon-Durey, M. A. et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15, 787–795 (2004).
Sellier-Leclerc, A. L. et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 18, 2392–2400 (2007).
Bienaime, F. et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 77, 339–349 (2010).
Caprioli, J. et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12, 297–307 (2001).
Noris, M. et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J. Am. Soc. Nephrol. 16, 1177–1183 (2005).
Fremeaux-Bacchi, V. et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41, e84 (2004).
Kavanagh, D. et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 2150–2155 (2005).
Kavanagh, D. et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol. Immunol. 45, 95–105 (2008).
Noris, M. et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362, 1542–1547 (2003).
Richards, A. et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 100, 12966–12971 (2003).
Fremeaux-Bacchi, V. et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 17, 2017–2025 (2006).
Goicoechea de Jorge, E. et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl Acad. Sci. USA 104, 240–245 (2007).
Roumenina, L. T. et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114, 2837–2845 (2009).
Frémeaux-Bacchi, V. et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112, 4948–4952 (2008).
Delvaeye, M. et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 345–357 (2009).
Dragon-Durey, M. A. et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555–563 (2005).
Józsi, M. et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111, 1512–1514 (2008).
Józsi, M. et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110, 1516–1518 (2007).
Abarrategui-Garrido, C., Martínez-Barricarte, R., López-Trascasa, M., de Córdoba, S. R. & Sánchez-Corral, P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114, 4261–4271 (2009).
Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in, CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115, 379–387 (2010).
Esparza-Gordillo, J. et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 14, 703–712 (2005).
Esparza-Gordillo, J. et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 43, 1769–1775 (2006).
Fremeaux-Bacchi, V. et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J. Med. Genet. 42, 852–856 (2005).
Cruzado, J. M. et al. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am. J. Transplant. 9, 1477–1483 (2009).
Le Quintrec, M. et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Transplant. 8, 1694–1701 (2008).
Martinez-Barricarte, R. et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 19, 639–646 (2008).
Blom, A. M. et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J. Immunol. 180, 6385–6391 (2008).
Caprioli, J. et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 12, 3385–3395 (2003).
Saunders, R. E. et al. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum. Mutat. 28, 222–234 (2007).
Dragon-Durey, M. A. et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 46, 447–450 (2009).
FH-aHUS Mutation Database [online], (2010).
Jablonski, M. et al. Kidney transplant outcome in atypical hemolytic uremic syndrome: the French experience. Am. Soc. Nephrol. Abstract #F-PO2074 (2009).
Heinen, S. et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum. Mutat. 27, 292–293 (2006).
Venables, J. P. et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 3, e431 (2006).
Zipfel, P. F. et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3, e41 (2007).
Heinen, S. et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114, 2439–2447 (2009).
Artz, M. A., Steenbergen, E. J., Hoitsma, A. J., Monnens, L. A. & Wetzels, J. F. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 76, 821–826 (2003).
Lahlou, A. et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF). Medicine (Baltimore) 79, 90–102 (2000).
Quan, A., Sullivan, E. K. & Alexander, S. R. Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 72, 742–745 (2001).
Loirat, C. & Fremeaux-Bacchi, V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr. Transplant. 12, 619–629 (2008).
Saland, J. M., Ruggenenti, P. & Remuzzi, G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 20, 940–949 (2009).
Strobel, S. et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25, 136–144 (2010).
Kwon, T. et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 23, 2088–2090 (2008).
Le Quintrec, M. et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am. J. Transplant. 9, 1223–1229 (2009).
Waters, A. M. et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am. J. Transplant. 10, 168–172 (2010).
Chan, M. R. et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am. J. Kidney Dis. 53, 321–326 (2009).
Geelen, J. et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr. Nephrol. 22, 371–375 (2007).
Nilsson, S. C. et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol. Immunol. 44, 1835–1844 (2007).
Davin, J. C. et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr. Nephrol. 24, 1757–1760 (2009).
Frémeaux-Bacchi, V. et al. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am. J. Transplant. 7, 2047–2051 (2007).
Ishii, H. & Majerus, P. W. Thrombomodulin is present in human plasma and urine. J. Clin. Invest. 76, 2178–2181 (1985).
Pratt, J. R., Basheer, S. A. & Sacks, S. H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat. Med. 8, 582–587 (2002).
Zheng, X. et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am. J. Transplant. 6, 2099–2108 (2006).
Pham, P. T. et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am. J. Kidney Dis. 36, 844–850 (2000).
Reynolds, J. C., Agodoa, L. Y., Yuan, C. M. & Abbott, K. C. Thrombotic microangiopathy after renal transplantation in the United States. Am. J. Kidney Dis. 42, 1058–1068 (2003).
Zarifian, A., Meleg-Smith, S., O'Donovan, R., Tesi, R. J. & Batuman, V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 55, 2457–2466 (1999).
Hastings, M. C. et al. Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy. Pediatr. Nephrol. 22, 742–746 (2007).
Ruggenenti, P. Post-transplant hemolytic-uremic syndrome. Kidney Int. 62, 1093–1104 (2002).
Schwimmer, J., Nadasdy, T. A., Spitalnik, P. F., Kaplan, K. L. & Zand, M. S. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am. J. Kidney Dis. 41, 471–479 (2003).
Ruggenenti, P., Noris, M. & Remuzzi, G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60, 831–846 (2001).
Al-Lamki, R. S., Bradley, J. R. & Pober, J. S. Endothelial cells in allograft rejection. Transplantation 86, 1340–1348 (2008).
Karthikeyan, V., Parasuraman, R., Shah, V., Vera, E. & Venkat, K. K. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am. J. Transplant. 3, 1289–1294 (2003).
Satoskar, A. A. et al. De novo thrombotic microangiopathy in renal allograft biopsies—role of antibody-mediated rejection. Am. J. Transplant. 10, 1804–1811 (2010).
Canaud, G. et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am. J. Transplant. 10, 2051–2060 (2010).
Kwon, O., Hong, S. M., Sutton, T. A. & Temm, C. J. Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am. J. Physiol. Renal Physiol. 295, F351–F359 (2008).
Waiser, J., Budde, K., Rudolph, B., Ortner, M. A. & Neumayer, H. H. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am. J. Kidney Dis. 34, 556–559 (1999).
Olie, K. H. et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am. J. Kidney Dis. 45, e12–e15 (2005).
Ardalan, M. R., Shoja, M. M., Tubbs, R. S., Esmaili, H. & Keyvani, H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am. J. Transplant. 8, 1340–1344 (2008).
Murer, L. et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J. Am. Soc. Nephrol. 11, 1132–1137 (2000).
Naesens, M., Kuypers, D. R. & Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481–508 (2009).
Liptak, P. & Ivanyi, B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat. Clin. Pract. Nephrol. 2, 398–404 (2006).
Ponticelli, C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin. Nephrol. 67, 335–340 (2007).
Andreoni, K. A., Brayman, K. L., Guidinger, M. K., Sommers, C. M. & Sung, R. S. Kidney and pancreas transplantation in the United States, 1996–2005. Am. J. Transplant. 7, 1359–1375 (2007).
English, J., Evan, A., Houghton, D. C. & Bennett, W. M. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44, 135–141 (1987).
Lanese, D. M. & Conger, J. D. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest. 91, 2144–2149 (1993).
Ramzy, D. et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 114 (Suppl.), I214–I219 (2006).
Al-Massarani, G. et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am. J. Transplant. 8, 2360–2367 (2008).
Fortin, M. C. et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am. J. Transplant. 4, 946–952 (2004).
Robson, M., Côte, I., Abbs, I., Koffman, G. & Goldsmith, D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am. J. Transplant. 3, 324–327 (2003).
Sartelet, H. et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am. J. Transplant. 5, 2441–2447 (2005).
Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).
Miriuka, S. G. et al. mTOR inhibition induces endothelial progenitor cell death. Am. J. Transplant. 6, 2069–2079 (2006).
Simmonds, J. et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 117, 2657–2661 (2008).
Bolovan-Fritts, C. A. & Spector, S. A. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 111, 175–182 (2008).
Petrogiannis-Haliotis, T. et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N. Engl. J. Med. 345, 1250–1255 (2001).
Taylor, C. M., Machin, S., Wigmore, S. J. & Goodship, T. H. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br. J. Haematol. 148, 37–47 (2010).
Fang, C. J. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111, 624–632 (2008).
The European Society for Paediatric Nephrology [online], (2010).
Nöthen, M. M. & Dewald, G. Dinucleotide repeat polymorphism at the human CD59 locus. Clin. Genet. 47, 165–166 (1995).
Rey-Campos, J., Rubinstein, P. & Rodriguez de Cordoba, S. Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J. Exp. Med. 166, 246–252 (1987).
Brown, K. M. et al. Influence of donor C3 allotype on late renal-transplantation outcome. N. Engl. J. Med. 354, 2014–2023 (2006).
Varagunam, M., Yaqoob, M. M., Döhler, B. & Opelz, G. C3 polymorphisms and allograft outcome in renal transplantation. N. Engl. J. Med. 360, 874–880 (2009).
Heeger, P. S. et al. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201, 1523–1530 (2005).
Liu, J. et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201, 567–577 (2005).
Raedler, H., Yang, M., Lalli, P. N., Medof, M. E. & Heeger, P. S. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am. J. Transplant. 9, 1784–1795 (2009).
Vieyra, M. B. & Heeger, P. S. Novel aspects of complement in kidney injury. Kidney Int. 77, 495–499 (2009).
Oyen, O. et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am. J. Transplant. 6, 412–418 (2006).
Conlon, P. J. et al. Renal transplantation in adults with thrombotic thrombocytopenic purpura/haemolytic-uraemic syndrome. Nephrol. Dial. Transplant. 11, 1810–1814 (1996).
Miller, R. B. et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol. Dial. Transplant. 12, 1425–1430 (1997).
Ashman, N. et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am. J. Transplant. 9, 424–427 (2009).
Midtvedt, K., Bitter, J., Dørje, C., Bjørneklett, R. & Holdaas, H. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation 87, 1901–1903 (2009).
Davin, J. C. et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am. J. Kidney Dis. 55, 708–711 (2010).
Davin, J. C., Strain, L. & Goodship, T. H. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr. Nephrol. 23, 1517–1521 (2008).
Hirt-Minkowski, P. et al. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol. Dial. Transplant. 24, 3548–3551 (2009).
Chatelet, V., Frémeaux-Bacchi, V., Lobbedez, T., Ficheux, M. & Hurault de Ligny, B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am. J. Transplant. 9, 2644–2645 (2009).
Boyer, O. et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am. J. Kidney Dis. 55, 923–927 (2010).
Cheong, H. I. et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr. Nephrol. 19, 454–458 (2004).
Remuzzi, G. et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 359, 1671–1672 (2002).
Remuzzi, G. et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation. Am. J. Transplant. 5, 1146–1150 (2005).
Jalanko, H. et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am. J. Transplant. 8, 216–221 (2008).
Saland, J. M. et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am. J. Transplant. 6, 1948–1952 (2006).
Saland, J. M. et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4, 201–206 (2009).
Parker, C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373, 759–767 (2009).
Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544–546 (2009).
Nürnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542–544 (2009).
Larrea, C. F. et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89, 903–904 (2010).
Zimmerhackl, L. B. et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362, 1746–1748 (2010).
Alexion clinical trials [online], (2010).
LFB Biotechnologies [online], (2010).
Sakai, M., Ikezoe, T., Bandobashi, K., Togitani, K. & Yokoyama, A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 45, 803–805 (2009).
Wagner, E. & Frank, M. M. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9, 43–56 (2010).
Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058–1066 (2001).
Eto, N. et al. Protection of endothelial cells by dextran sulfate in rats with thrombotic microangiopathy. J. Am. Soc. Nephrol. 16, 2997–3005 (2005).
Jungraithmayr, T. C. et al. Successful renal transplantation in a 10-year old boy with factor H associated hemolytic uremic syndrome (aHUS) with plasmapheresis and eculizumab. 5th Congress of the International Pediatric Transplantation Association, Istanbul, LB17 (2009).
Acknowledgements
The authors are grateful to M. Essig (Service de Néphrologie, CHU de Limoges, Limoges, France), B. Moulin (Service de Néphrologie et Hémodialyze, Hôpital Civil, Strasbourg, France) and E. Rondeau (Service de Néphrologie, Hôpital Tenon, Paris, France) for providing updated data on the outcomes of their patients transplanted under pre-emptive plasma therapy. We would also like to thank B. Hurault de Ligny (Service de Néphrologie, CHU de Caen, Caen, France), M. Lozano (Department of Hemotherapy and Hemostasis, Hospital Clinic Barcelona, Barcelona, Spain) and J. Nürnberger (University Duisburg-Essen, Essen, Germany) for providing updated data on the late outcomes of their patients treated with eculizumab. The renal transplant department of Hôpital Necker belongs to the Fondation Centaure Network, which supports clinical and basic research in organ transplantation.
Author information
Authors and Affiliations
Contributions
All authors contributed substantially to the discussion of this article's content and reviewed/edited the manuscript before submission. J. Zuber and M. Le Quintrec researched data for the article and J. Zuber, C. Loirat, and V. Fremeaux-Bacchi wrote the article.
Corresponding author
Ethics declarations
Competing interests
J. Zuber and V. Frémeaux-Bacchi have received honoria from Alexion Pharmaceuticals for invited lectures. C. Loirat has received grant research support from Alexion Pharmaceuticals and has consulted for LFB Biotechnologies (as a member of the board of experts for the development of plasma-derived concentrated complement factor H). C. Legendre is a member of the French Advisory Board for Alexion Pharmaceuticals. M. Le Quintrec and R. Sberro-Soussan declare no competing interests.
Rights and permissions
About this article
Cite this article
Zuber, J., Le Quintrec, M., Sberro-Soussan, R. et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7, 23–35 (2011). https://doi.org/10.1038/nrneph.2010.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.155
This article is cited by
-
Drug-induced de novo thrombotic microangiopathy diagnosed 2 years after renal transplantation: a case report and literature review
Renal Replacement Therapy (2023)
-
The role of complement in kidney disease
Nature Reviews Nephrology (2023)
-
A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab
BMC Nephrology (2020)
-
Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
Experimental Hematology & Oncology (2017)